Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Laurie K Pearson"'
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1366-1372 (2021)
Myeloid sarcoma (MS) is a rare extramedullary manifestation of acute myelogenous leukemia (AML). The mass is composed of primitive myeloid cells that can occur in a variety of organs, most commonly the skin, lymph nodes, GI tract, bone, breast, and C
Externí odkaz:
https://doaj.org/article/b9e3c5c09ff247eeae780ac714331b9d
Autor:
Laurie K Pearson, Anita J Kumar, John B Wong, Jonathan W. Friedberg, Amy LeClair, Susan K. Parsons
Publikováno v:
Blood. 140:7917-7918
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50e8fdf6415c455860b888511f8fd529
https://doi.org/10.1182/blood-2022-156496
https://doi.org/10.1182/blood-2022-156496
Publikováno v:
Blood. 140:12423-12424
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::541f39643b5afabe4ef98c7d10123d93
https://doi.org/10.1182/blood-2022-156499
https://doi.org/10.1182/blood-2022-156499
Autor:
Renata Walewska, Ryan Jacobs, Arvind Arumainathan, Frederick Lansigan, Paul M. Barr, Christopher P. Fox, John M. Pagel, Stephen J. Schuster, Catherine C. Coombs, Laurie K Pearson, Mazyar Shadman, Chaitra S. Ujjani, Anthony R. Mato, Toby A. Eyre, Angus Broom, Bruce D. Cheson, Satyen H. Gohill, Brian T. Hill, Alan P Skarbnik, John N. Allan, Francesco Forconi, Nicole Lamanna, Lindsey E. Roeker, Danielle M. Brander, Harriet S. Walter
Publikováno v:
Br J Haematol
Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton’s tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3180027c6ab1c16dd8426877bafd5a9
https://doi.org/10.1111/bjh.16271
https://doi.org/10.1111/bjh.16271
Autor:
Laurie K Pearson, Charlene C. Kabel, Paul M. Barr, Bruce D. Cheson, Chaitra S. Ujjani, Danielle M. Brander, Anthony R. Mato, Ryan Jacobs, Joanna Rhodes, Allison M. Winter, Amy A Kirkwood, Nicole Lamanna, Brian T. Hill, Alan P Skarbnik, Frederick Lansigan, John M. Pagel, Maryam Sarraf Yazdy, AnnaLynn M. Williams, Anna Schuh, Andre Goy, Hande H. Tuncer, Stephen J. Schuster, Christopher P. Fox, Colleen Dorsey, Sivraj Muralikrishnan, Mazyar Shadman, Toby A. Eyre, Arun K Singavi, John N. Allan, Nirav N. Shah, Catherine C. Coombs, Hannah Morse, Neil Bailey, Andrea Sitlinger, Chadi Nabhan, Lindsey E. Roeker
Publikováno v:
Clin Cancer Res
Purpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e4f0a616159e728eef4f8a755acc822
https://doi.org/10.1158/1078-0432.ccr-19-0361
https://doi.org/10.1158/1078-0432.ccr-19-0361
Autor:
Toby A. Eyre, John N. Allan, Allison M. Winter, Bruce D. Cheson, Hande H. Tuncer, Frederick Lansigan, Neil Bailey, Andre Goy, Paul M. Barr, Stephen J. Schuster, Danielle M. Brander, John M. Pagel, Arun K Singavi, Maryam Sarraf Yazdy, AnnaLynn M. Williams, Nirav N. Shah, Colleen Dorsey, Lindsey E. Roeker, Brian T. Hill, Alan P Skarbnik, Sivraj Muralikrishnan, Chadi Nabhan, Christopher P. Fox, Anna Schuh, Catherine C. Coombs, Mazyar Shadman, Chaitra S. Ujjani, Ryan Jacobs, Amy A Kirkwood, Andrea Sitlinger, Anthony R. Mato, Laurie K Pearson, Joanna Rhodes, Hannah Morse, Nicole Lamanna
Publikováno v:
Blood. 132:4410-4410
Introduction: Venetoclax (Ven), an oral BCL2 inhibitor, is approved for the treatment (tx) of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Ven is generally well tolerated, and side effects observed in clinical trials have been consis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0ec7abe702e452d05a0ed64e931d418
https://doi.org/10.1182/blood-2018-99-118159
https://doi.org/10.1182/blood-2018-99-118159